|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Cross-talk between the insulin-like growth factor(IGF) axis and membrane integrins to regulate cell physiology显示文摘 | Beattie J McIntosh L van der Walle CF | | 0，，03： | 1 |
| 2 | A comparison of catch trial methods used in standard automated perimetry in glaucoma patients显示文摘 | Wall M Doyle CK Brito CF | 2008 | Journal of Glaucoma2008，17，： | 1 |
| 3 | Therapeutic antibodies: market considerations, disease targets and bioprocessing显示文摘 | Elvin JG Couston RG van der Walle CF | 2013 | Int J Pharm2013，440，1： | 1 |
| 4 | Therapeutic antibod- ies : market considerations, disease targets and bioprocessing 显示文摘 | Elvin JG Couston RG van der Walle CF | 2013 | Ira J Pharm2013，440，1： | 1 |
| 5 | Mieroemulsions for oral delivery of insulin:design, development and evaluation in strepto- zotoein induced diabetic rats 显示文摘 | Sharrna G Wilson K van der Walle CF | 2010 | European Journal of Pharmaeeuties and Biopharmaeeutics2010，76，2： | 1 |
| 6 | Determining drug spatial distribution within controlled delivery tablets using MFX imaging显示文摘 | RIGBY SP VAN DER WALLE CF RAISTRICK JH | 2004 | J Controlled Release2004，96，1： | 1 |
| 7 | Current approaches to stabilising and analysing proteins during micro-encapsulation in PLGA 显示文摘 | WALLE CF SHARMA G RAVI K M | 2009 | Expert Opin Drug Deliv2009，6，2： | 1 |
| 8 | 显示文摘 | Keller G Wall C Andrew Z CF | 1998 | Blood1998，92，3： | 1 |
| 9 | Therapeutic anti- bodies: Market considerations, disease targets and bioprocess- ing 显示文摘 | Elvin JG Couston RG Van Der Walle CF | 2012 | Int J Pharm2012，，： | 1 |
| 10 | Therapeutic anti- bodies: market considerations, disease targets and bioproces- sing 显示文摘 | Elvin JG Couston RG van der Walle CF | 2013 | Int J Pharm2013，，： | 1 |
| 11 | Current approaches to stabilising and analysing proteins during microencapsu lation in PLGA显示文摘 | van der Walle CF Sharma G Ravi Kumar M | 2009 | Expert Opin Drug Deliv2009，6，2： | 1 |
| 12 | Therapeutic antibodies: market considerations, disease targets and bioprocessing 显示文摘 | Elvin JG Couston RG van der Walle CF | 2013 | Int J Pharm2013，440，： | 1 |
| 13 | Therapeu- tic antibodies:Market considerations, disease targets and biopro- cessing 显示文摘 | ELVIN JG COURSTON RG VAN DER WALLE CF | 2013 | Int J Pharm2013，440，1： | 1 |
| 14 | A freeze-dried formulation of bacteriophage encapsulated in biodegradable microspheres显示文摘 | PUAPERMPOONSIRI U SPENCER J van der WALLE CF | 2009 | Eur J Pharm Biopharm2009，72，1： | 1 |
| 15 | Microemulsions for oral delivery of insulin;design,development and evaluation in streptozotocin induced diabetic rats显示文摘 | Sharma G Wilson K van der Walle CF | 2010 | European Journal of Pharmaceutics and Biopharmaceutics2010，76，2： | 1 |
| 16 | NMR and confocal microscopy studies of the mechanisms of burst drug release from PLGA microspheres 显示文摘 | Messaritaki A Black SJ van der Walle CF Rigby SP | 2005 | J Control Release2005，108，23： | 1 |
| 17 | NMR and confocaI microscopy studies of the mechanisms of burst drug release from PLGA microspheres 显示文摘 | MESSARITAKI A BLACK SJ VAN DER WALLE CF | 2005 | J Control Release2005，108，23： | 1 |
| 18 | Antacid co-encapsulated polyester nanoparticles for peroral delivery of insulin:Development,pharmacokinetics,biodistribution and pharmacodynamics显示文摘 | Sharma G van der Walle CF Ravi Kumar MN | | 0，，： | 1 |
| 19 | 收缩压干预试验中不同种族和民族间临床结局:一项随机临床试验显示文摘收缩压干预试验(systolic blood pressure intervention trial,SPRINT)结果显示,与降压目标≤140mmHg(标准治疗组)相比,以目标收缩压≤120mmHg的强化治疗更能减少心血管事件的发生;然而,目前尚不清楚是否在所有种族/族群间都有相似的效应。 | Still CH Rodriguez CJ Wright JT Jr Craven TE Bress AP Chertow GM Whelton PK Whittle JC Freedman BI Johnson KC Foy CG He J Kostis JB Lash JP Pedley CF Pisoni R Powell JR Wall BM 陈云 叶鹏 | 2018 | 中华高血压杂志2018，26，10： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员